posted
EDOT.com / Nanoviricides, Inc. Announces New CEO Wednesday June 8, 6:00 am ET
WEST HAVEN, Conn.--(BUSINESS WIRE)--June 8, 2005--Nanoviricides, Inc. (Pink Sheets:ECMM - News) announced that Dr. Eugene Seymour, M.D. had been hired as the Company's new Chief Executive Officer and Chairman of the Board. ADVERTISEMENT
Dr. Seymour was originally trained as a chemist, but decided to attend medical school in preparation for a career as a clinical investigator. Following postgraduate medical training, he obtained a Master's degree in the Epidemiology of Infectious Diseases at UCLA. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. Left UCLA after two years and joined USC faculty as Associate Professor.
Dr. Seymour served in the Medical Corps of US Army Reserve during the Vietnam era and attained the rank of Major. In late 1981, he began treating patients with a strange new disease affecting primarily the gay population. Because of the stigma associated with AIDS, he worked with a number of celebrity patients whose identity could not be disclosed for fear of being ostracized in the entertainment community.
In 1986, he was requested by the US government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. His laboratory ended up testing over 50,000 people.
In 1989, he founded SDS, Inc, raised the capital and developed the rapid HIV antibody blood test (Hema-Strip). He took the company public in 1993 as CEO/ President. Under his direction, the company conducted research studies in Africa, Asia, South and North America. The Hema-Strip was approved in a number of countries including Canada, Great Britain and Vietnam, among others, and currently is in front of the FDA, awaiting approval in the US.
He left SDS in 1996 to form a non-profit Foundation, which funded both testing and training programs for health workers in Asia and Africa. He became a consultant to the UN Global Program on AIDS and was sent to a number of different countries, (Lithuania, Latvia, Estonia and Russia) to interact with local physicians and assist them in setting up testing programs.
Two years later, he became Director of Strategic Alliances at a medical education startup called Medschool.com. Alan Patricof, a New York venture capitalist who subsequently invested $35 million in the venture, currently named MedSyn.com, eventually acquired this company. Dr. Seymour now spends his time as a private investor evaluating evolving companies in the field of biotechnology.
Dr. Seymour holds 8 issued patents, and is married with three children, two of whom are physicians. He has been passionately involved in the treatment and destruction of HIV/AIDS for nearly twenty years.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
he was, of nanoviricide, they merged with a shell and we know those owners own the company, obviously they probably know nothing about virus work, so they have the Dr. running the show as they should.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
quote:Originally posted by cruz: this has dropped big time.
its so new, people are wondering what this thing is worth, so am I. more news from this am.
Edot.com, Inc. Announces New Chief Regulatory Officer Wednesday June 8, 9:29 am ET
MIAMI--(BUSINESS WIRE)--June 8, 2005--Edot.com, Inc. (Pink Sheets:ECMM - News), announced that Krishna Menon joined the Company's scientific advisory board and accepted the position of Chief Regulatory officer. Dr. Menon is a former employee of the year President's award winner at Eli Lilly, having led several blockbuster drug projects there. "I'm very excited at the prospect of joining Nanoviricide," Dr. Menon noted, "this technology represents, in my opinion, a market leading concept. It allows for a textbook finish for so many well conceived APIs, allowing delivery to target cells with lowest dosage, which increases efficacy and reduces toxicity." Dr. Menon returned from a trip to Singapore, where he was a keynote speaker at the drug delivery summit.
The Company plans to begin its animal trials this summer on the first of its targeted anti-viral nanoviricides(TM). Dr. Krisna Menon, Chief Regulatory Officer will be supervising and monitoring the animal studies.
Dr. Menon is a well known Pharmaceutical Scientist and Executive. He was awarded the Employee of the Year, Presidents Award (1999) at Eli Lilly, where he was a co-inventor of two drugs GEMZAR and ALIMTA which account for nearly one billion dollars in annual sales. Prior to that, he was Senior Research Scientist at Bayer. At present, he is on the board of directors of KARD Scientific, MA, and Biological Supplies, NY, and scientific advisor to Nexus Pharmaceuticals.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
so odd, so odd--showing last at .20 even though ask is .17...I may hold till news of animal trials...what're youse guys thinking? They seem to have well-credentialed folks on board...
posted
i am sitting on the sideline right now. i hope time is on my side. i just hope i don't miss the run. you are right keithsan - it's hard to figure out what this is worth.
Posts: 1421 | From: USA | Registered: Dec 2004
| IP: Logged |
posted
Hot Stocks to Watch for Thursday, June 09, 2005: Adding Enterprise Management! 06/09/2005 09:09 WESTON, FL -- (MARKET WIRE) -- 06/09/05 -- ************* announces the following stocks to its Hot Stocks List: Nanoviricides, Inc. (OTC: ECMM), Boston Scientific Corporation (NYSE: BSX), JDS Uniphase Corporation (NASDAQ: JDSU), RF Micro Devices Inc. (NASDAQ: RFMD)
Nanoviricides, Inc. (OTC: ECMM) just announced that Dr. Eugene Seymour, M.D. had been hired as the Company's new Chief Executive Officer and Chairman of the Board. ECMM also announced that Krishna Menon joined the Company's scientific advisory board and accepted the position of Chief Regulatory officer. Dr. Menon is a former employee of the year President's award winner at Eli Lilly, having led several blockbuster drug projects there.
Other stocks highlighted include Boston Scientific Corporation (NYSE: BSX): Hot Stocks List, up 1% on 6 million shares, JDS Uniphase Corporation (NASDAQ: JDSU): Hot Stocks List, down 1% on 86 million shares, RF Micro Devices Inc. (NASDAQ: RFMD): Hot Stocks List, up 1% on 2 million shares.
"Economists have ratcheted back their estimates for the pace of U.S. growth since the March durable goods number came in much lower than expected. The consensus estimate was hovering around 3.6% for GDP, but now they have been scaled down to about the 3% to 3.5% range. Shipments of core capital goods, a measure of business investment, dropped 1.1% in March." More is available at: http://www.*************.
*************'s Daily Stock Updates:
*************, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.*************.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.************* or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated twenty five thousand dollars for ECMM. CRG intends to sell its shares. CRG has sold approximately zero ECMM shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
CONTACT: Charles T. Tamburello Capital Research Group Inc 954-217-9555
Posts: 1421 | From: USA | Registered: Dec 2004
| IP: Logged |
posted
Former Employee of the Year at Eli Lilly and Company Accepts Chief Regulatory Officer Position at EDot.com/Nanoviricides, Inc. Thursday June 9, 6:00 am ET Dr. Krishna Menon, VMD, MRCS, PhD., Co-Inventor of Two "Blockbuster Drugs" Having Nearly a Billion Dollars in Annual Sales
MIAMI--(BUSINESS WIRE)--June 9, 2005-- EDot.com, Inc. (Nanoviricides) (Pink Sheets:ECMM - News), announced that Dr. Krishna Menon accepted the position of Chief Regulatory officer. Dr. Menon is a former "Employee of the Year" and "President's Award" winner at Eli Lilly, having led several blockbuster drug projects there.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
Cruz--it turned on me, personally, I'm taking this PERSONALLY,lol--I'm gonna be stubborn. If that's wrong, I'm wrong, but I think at some point people will see the value, so I'm long, officially long...the technology makes sense to me, they've got props, so even though it started as run play, I think it will go eventually...
posted
wassup on this stock, anyway?...geek stock...huge potential...great find...great pick...good PR's (once they started releasing intra-day) appropriate technology, excellent props on the prinicipals...and it falls from 30-ish to 10-ish? feel like I'm in Superman's Bizarro world...
posted
yessir, and yep, saw it...up 50+ %, but can find no reason why. Like i said, geeky, man. Been trading above ask for about 2 1/2 hours, at .11, now .109.
b x a is .09 x .095
good volume, too...
Did find a more recent PR than I knew about, but still, it's a week old. Started to post something, but it's so odd...
Tex, after the pr, the mm's dip it to get traders to sell. sometimes this is dillution and not an mm fake out and its tough on pinks to know what is happening.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
the day we bought it had a big jump, so it usually consolidates before going again, it also could've consolidated and sat so this is nice too see.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
NEW YORK & MIAMI--(BUSINESS WIRE)--June 21, 2005--Nanoviricide, Inc./EDot.com, Inc. (Pink Sheets:ECMM - News): "In addition to being a world famous physician and administrator, he is a former director of Pfizer; a former director of Tularik, Inc., acquired by Amgen; and a cofounder of Aton Pharmaceuticals, later acquired by Merck,"...said Eugene Seymour, MD, CEO of the emerging biopharmaceutical nanotechnology company that continues to attract Internationally renowned medical researchers and advisors. Nanoviricide, Inc./EDot.com, Inc. (Pink Sheets:ECMM - News), is pleased to announce that Paul A. Marks, MD, has joined the Company as Chairman of the Scientific Advisory Board. Dr. Marks has a long and distinguished career as a physician, scientist, teacher and medical administrator. As President and Chief Executive Officer, Dr. Marks led Memorial Sloan-Kettering Cancer Center for 19 years, beginning in 1980. He remains a vital part of MSKCC as President Emeritus and Member of the Sloan-Kettering Institute. http://www.mskcc.org/mskcc/html/53984.cfm
"We are very excited that a medical researcher of Dr. Marks' stature is joining us. In our mission to create new anti-viral drugs based on nanotechnology principles, we will welcome his advice and counsel. His record is outstanding. In addition to being a world famous physician and administrator, he is a former director of Pfizer; a former director of Tularik, Inc., acquired by Amgen; and a cofounder of Aton Pharmaceuticals, later acquired by Merck. "His having been involved in drug discovery for anti-cancer drugs means that his advice will be invaluable as we develop our new anti-viral drugs," said Eugene Seymour, MD, CEO
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
same reason we bought tex. we bought on the run up others waited for the dip. not everyone trading pennies is a daytrader...
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
posted
from what i gather, company is worth the holding risk, these guys are the real deal, not penny scumbags. The product may or may not work, i know nothing about viruses. Basically people will hold good companies that they're not too afraid of an RS or some other trick on, holding a bunch of nice shells is good to
these guys also hit their workplaces with the new company and if those people think it'll work, they'll buy in. looks good from here. moving with NO hype which is perfect.
Posts: 9110 | From: boston, ma | Registered: Jan 2004
| IP: Logged |
from the little I know about viruses, the nano approach makes sense. I *do* like the props on the principals, ain't wild 'bout their PR guy, though--we had a coupla go-rounds, which I think I posted. Anyway, yup, like 'em...happy to see the action...thanks, KS
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
![[Wink]](wink.gif)
